Kevin Barber has more than 30 years of experience in product development, regulatory strategy, and biomedical research. He is a seasoned leader in integrated product development, having guided regulatory and clinical strategies for drugs, biologics, and medical devices from preclinical phases through marketing applications and post-approval lifecycle management.

Throughout his career, Kevin has successfully supported over 80 development programs and played a key role in 18 product approvals worldwide. He has prepared and filed more than 100 INDs/CTAs and contributed to over 80 marketing applications across the United States, Canada, Europe, Latin America, Australia, and New Zealand. His extensive therapeutic expertise spans oncology, CNS/neurology, immunology, cardiovascular disease, infectious diseases, dermatology, and cell/gene therapy, among others

Before joining Everest, Kevin served as Senior Vice President of Regulatory Strategy & Submissions at Rho, Inc., where he built and scaled the company’s global regulatory consulting and submissions practice, delivering year-over-year growth in integrated product development services. He has also held senior leadership roles at Novan, Inc., Actavis (formerly Watson Pharmaceuticals), and Cato Research, where he provided strategic oversight for regulatory and clinical programs across diverse therapeutic areas.

Kevin holds a Ph.D. in Biomedical Engineering from Duke University and both an M.S. and B.S. in Aerospace Engineering from Virginia Tech. He is Regulatory Affairs Certified (RAC) and a certified Project Management Professional (PMP).